Irazú Oncology

Overview

Founded in 2022, Irazú Oncology is pioneering a new generation of cancer immunotherapies through our proprietary OMV (outer membrane vesicle) technology. Building upon over 15 years of groundbreaking research at the University of Maryland’s Center for Vaccine Development and Global Health, we’re dedicated to breaking barriers in cancer care.